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Background. Alternative approaches for managing depression are oen sought and herbal mixtures are widely used in China. e
aim of this paper was to provide an overall picture of the current evidence by analysing published systematic reviews and presenting
a supplementary systematic review of trials in Western databases. Methods. Searches were conducted using AMED, Cochrane
Library, EMBASE, MEDLINE/PubMed, PsycINFO, and trial registers. Results were screened and selected trials were evaluated by
two reviewers working independently. Systematic reviews were identi�ed and assessed using key criteria. Results. Five systematic
reviews were located addressing the Chinese literature, adjunctive use of Chinese herbs, and the formulae Chaihu-Shugan-San,
Xiao Yao San, and Free and Easy Wanderer Plus. e supplementary review located 8 trials, 3 of which were not included in
previous reviews. Positive results were reported: no signi�cant diﬀerences from medication, greater eﬀect than medication or
placebo, reduced adverse event rates when combined or compared with antidepressants. However, limitations in methodology and
reportingwere revealed.Conclusions. Despite promising results, particularly forXiaoYao San and itsmodi�cations, the eﬀectiveness
of Chinese herbal medicine in depression could not be fully substantiated based on current evidence. Further well-designed, well-
reported trials that re�ect practice may be worth pursuing.
1. Introduction
Knowledge about the use of complementary therapies by
people with mental illness is increasing. Previous studies
have demonstrated that psychiatric disorders are common
among those seeking to use complementary and alternative
medicine (CAM) and that anxiety and depression are among
the most common reasons for people to seek care from com-
plementary practitioners [1–4]. Over 50% of respondents
self-diagnosed with “anxiety attacks” or “severe depression”
reported using complementary and alternative therapies to
treat their condition [2]. A recent survey in England also
found that presence of anxiety or depression was an indepen-
dent predictor of complementary therapy use [5]. People with
mental illness appear to derive a broad range of bene�ts from
complementary practices and these include enhancement
of social, spiritual, general, and self-functioning [6]. One
survey of women with depression revealed active seeking
for treatments based on “natural approaches” and for those
that match the individual’s own values and beliefs [7]. People
with depression may also be seeking to avoid adverse eﬀects
associated with conventional medication. However, CAM
use has been found to be common even in those taking
prescription drugs [5].
Kessler et al. [2] found that use of herbs or diet supple-
ments was particularly prevalent in those with psychiatric
problems. Use of CAM in the USA increased by 2% between
2002 and 2007 [8] with natural products reported to be the
most frequently used therapies. Similar increases have been
observed in Australia [9] while use in the UK continues to
be substantial [5]. Users were found to be more likely to have
received mental health and primary care treatment and to be
dissatis�ed with their overall healthcare than nonusers [10].
Chinese herbal medicines were not speci�cally mentioned,
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but several of the herbs listed are included in Chinese herbal
formulae. e UK survey also revealed frequent use of herbs
but limited reported use speci�cally of Chinese herbs [5]. In
contrast, 7% of participants in a national survey in Australia
reported using Chinese herbal medicine, of whom 32.9% had
visited a Chinese herbal medicine practitioner [11].
It is diﬃcult to fully assess the extent of use of Chinese
herbs in depression outside China. Chinese herbs may be
less likely to be reported in surveys as participants may be
unable to name the speci�c herbs that they have received.
Additionally, in contrast to “Western” herbs, access to Chi-
nese herbs is generally via consultation with a practitioner
rather than purchase over the counter which limits their
use somewhat. Patterns of use may also vary according to
ethnic group and be higher in those who consider Chinese
medicine to be their primary medical system. For example,
use of herbs was shown to be greater in Chinese and Japanese
women in midlife than in Whites and African Americans
[12]. Considerable promotion of the bene�ts of Chinese
herbs is also found on the internet suggesting that use may
be more widespread than is apparent from surveys.
Numerous systematic reviews and research papers have
been published on the eﬀects of Western herbs such as
St John’s wort (Hypericum perforatum) in the treatment of
depression (e.g., [13–15]). Chinese herbs appear to have
received less attention although there has been research
interest in one speci�c formula, �iao �ao San. Systematic
reviews of the evidence on Chinese herbs in depression have
been published previously but none has addressed all RCTs
of Chinese herbs in the Western literature.
2. Aim
e aim of this paper was to assess the evidence on Chinese
herbal medicine treatments for depression based on previous
systematic reviews plus a supplementary systematic review
of trials in the Western literature. A secondary aim was to
explore the proportion of studies on this topic that can be
found in Western databases.
3. Materials andMethods
3.1. Searches. Randomised controlled trials (RCTs) of the
treatment of depression with Chinese herbal medicine
were located by searching AMED, EMBASE, MEDLINE,
PsycINFO, PubMed, Cochrane Field for Complementary
Medicine website, and the Clinical Trials Register of the
Cochrane Collaboration Depression, Anxiety & Neurosis
Group (CCDANTR). Only trials published in English were
included at this stage. In the second stage, more compre-
hensive searches were conducted and trials in all languages
were included. e above databases plus British Nursing
Index (BNI) were searched from inception to July 2010 using
the Ovid interface. e search strategy was as follows: exp
depression/ OR exp depressive disorder/ OR exp depressive
disorders/ OR exp major depression/ OR depressed.ti,ab. OR
depression.ti,ab. OR depressive.ti,ab. OR dysthymi∗.ti,ab. AND
exp drugs, chinese herbal/ OR exp Medicine, Chinese Tradi-
tional/ OR expMedicine, Oriental Traditional/ OR exp chinese
drug/ OR exp chinese medicine/ OR exp chinese herb/ OR (exp
medicinal herbs/ AND chinese.mp.) OR (chinese adj3 herb∗)
OR (chinese.ti,ab. AND herb∗.ti,ab.). Cochrane CENTRAL
was searched and a search was conducted of the Cur-
rent Controlled Trials metaregister (http://www.controlled-
trials.com/mrct/) to identify possible unpublished trials. e
most recent search for trials was carried out in July 2011.
Systematic reviews were identi�ed from the above
searches plus searches of the Cochrane Register of Systematic
Reviews and the Database of Abstracts of Reviews of Eﬀects
(DARE). Searches for systematic reviews continued up to July
2012.
Search results were screened for trials by two reviewers
working independently using the following inclusion criteria.
(i) Participants: diagnosed with clinical depression using
conventional or traditional Chinese criteria. Trials
in which participants with diﬀerent diagnoses were
treated (i.e., depression or bipolar disorder) were
included if outcomes were reported separately for
patients with depression.
(ii) Interventions: any intervention using Chinese herbal
formulae (combinations of herbs) or single Chinese
herbs.
(iii) Comparison interventions: included placebo, no
treatment, or any active treatment.
(iv) Outcomes: improvement in depression (partial or
complete alleviation of symptoms), as measured by
validated outcome measure, clinical assessment of
improvement, and participants’ subjective experi-
ences where reported.
Trials in which Chinese herbs were combined with
other complementary therapies (i.e., Chinese herbs and
acupuncture) were excluded. Studies on participants with
depression associated with other conditions, for example, a
medical/physical condition, menopause, premenstrual syn-
drome, or bipolar disorder were identi�ed initially. �owever,
as the herbal mixtures used may have had eﬀects other than
on depression, the main data analysis focused on those in
depression not associated with another condition. Selections
were compared and diﬀerences resolved by discussion.
Systematic reviewswere identi�ed by one researcher (KP)
using the following inclusion criteria: reviews of Chinese
herbal medicine in depression reported to be systematic and
including methods for searching and selection of studies.
3.2. Data Extraction and Assessment of Methodological Qual-
ity. Key criteria were used for systematic reviews. ese
included focus, date of searches, sources, inclusion criteria,
extraction and appraisal methods, number of trials included,
method of synthesis of results, and conclusions. A data
extraction sheet was designed to capture key data from trials
and allow an accurate comparison of the studies selected.
Translations were obtained for studies published in Chinese.
Data collected included details of study design, participants,
diagnostic criteria, interventions, outcomes measures, and
results for the primary outcome measure.
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RCTs were evaluated using two rating scales: the Jadad
criteria, use of which results in a score of between 0 and 5
based on 3 aspects of the methods: randomisation, blinding,
and extent of followup [16]. is scale places great emphasis
on blinding, which may not be feasible in trials involving
mixtures of Chinese herbs. erefore, a second more com-
prehensive scale was deemed necessary. e checklist pro-
posed by Downs and Black [17] was considered appropriate.
Previous reviews had found that there was good correlation
with Jadad [16] andhad independently validated its accuracy
[18, 19]. Downs and Black [17] use a checklist of 27 questions
which are intended to give broader overview of the methods
used in RCTs and non-RCTs. e �nal question relating to
power was adapted so that trial either scored 0 if power was
not discussed or 1 if a power calculation was conducted and
suﬃcient numbers recruited. e total possible score was,
therefore, 28. Trials scoring 3 or more on the Jadad scale were
considered to be at low risk of bias [16]. e approach taken
by Malcomson et al. [20] was to consider trials scoring 50%
or more on the Downs and Black scale as of good quality.
In this paper, total scores for both scales and key risk of bias
measures are reported.
4. Results
4.1. Previously Published Systematic Reviews. Six reports of
5 systematic reviews were identi�ed [21–26]. Each of these
focused on a speci�c aspect: trials in the Chinese literature
[21], trials of the speci�c herbal formulae Xiao Yao San
[22, 23], Free and Easy Wanderer Plus (a modi�ed version of
Xiao Yao San) [24], and Chaihu-Shugan-San [25], and trials
of Chinese herbs as adjunctive treatment [26].
e �rst of these systematic reviews included 18 tri-
als found by searching Chinese databases [21]. e trials
involved a total of 1,260 patients and included trials in
depression associated with various conditions such as cancer,
stroke, and the menopause.e authors concluded that there
was no evidence to support a bene�cial eﬀect in depression.
e �ndings are diﬃcult to interpret and the validity of
the conclusions is unclear. Trials of combined treatment
(acupuncture plus herbs) were included as were those in
which treatment appeared to be aimed at the medical condi-
tion rather than depression. Assessment of quality involved
assigning Jadad scores but these were not reported. A meta-
analysis was conducted but the results of trials comparing
Chinese herbs against placebo and those comparing Chinese
herbs against active treatment appear to have been combined
rather than reported separately.
A second systematic review focused speci�cally on Xiao
Yao San (also known as Free and Easy Wanderer Powder
or Rambling Powder) [22, 23]. is formula together with
a modi�ed version, Free and Easy Wanderer Plus (Jia wei
Xiao Yao San or augmented Xiao Yao San) are two of
the more frequently used formulae in Chinese medicine
[27]. Two similar reviews have been published: the �rst,
published in Chinese, included 32 trials (2,253 patients)
and the second, published in English including 26 trials
(1,837 patients) [22, 23]. e following comments relate to
the second publication. e authors concluded that Xiao
Yao San combined with antidepressants was more eﬀective
than antidepressants alone. Adverse eﬀects were reported
for antidepressants but not in relation to Xiao Yao San. e
majority of trials were found to be of poor methodological
quality. e conclusions also need to be interpreted in the
context of potential publication bias as revealed by a funnel
plot which demonstrated signi�cant asymmetry. ere was
also considerable variation between the formulae used in the
trials: only 8 trials used the traditional formula for Xiao Yao
San, the remaining trials using a modi�cation of the original
formula. e total number of herbs used in each trial varied
between 7 and 17.
e third review which was also published in 2011
addressed trials of Free and Easy Wanderer Plus [24].
Searches of Chinese and Western databases were carried out
and 14 trials selected, all conducted in China and 9 of which
included participants with major depression. Only trials
scoring at least 3 on the Jadad scale were included, which
had resulted in a further 50 trials being excluded from the
meta-analysis.e authors concluded that the herbal formula
may be eﬀective in depression, may enhance conventional
antidepressants, and may have a better safety pro�le than
standard antidepressants.
In the �rst of the reviews published in 2012, English and
Chinese databases were searched for RCTs in which Chi-
nese herbs were used in combination with antidepressants
[26]. Methods appeared rigorous and results presented as
weighted mean diﬀerence (WMD) based on Hamilton rating
scale for depression (HAM-D) scores. Seven RCTs involving
576 participants were identi�ed. Meta-analysis indicated
that integrated traditional and Western medicine based on
syndrome diﬀerentiation produced a greater reduction in
mean HAM-D scores than Western medicine alone (WMD
−2.39 95% CI −2.96, −1.83). No serious adverse eﬀects were
reported for combined treatment, but all trials were evaluated
as being at risk of bias or the risk of bias was unclear.
e ��h systematic review was also published in 2012
[25]. A range of Western and Chinese databases were
searched for trials of the formula, Chaihu-Shugan-San in
depression, and papers were selected by two researchers.
Ten RCTs involving 835 subjects were included. Meta-
analyses based on 6 RCTs indicated that Chaihu-Shugan-
San in combination with various selective serotonin reuptake
inhibitors (SSRIs) was more eﬀective that antidepressant
drugs alone based on HAM-D scores (WMD = −3.56; 95%
CI −5.09 to −2.03). Based on two trials, Chaihu-Shugan-San
as monotherapy was also more eﬀective than antidepressants
in improving depressive symptoms (WMD = −3.09; 95% CI
−5.13 to −1.06). No serious adverse events were reported. As
with previous reviews, all studies were judged to be of poor
methodological quality and at risk of bias.
No systematic reviews were found in which Western
databases were searched for trials of all Chinese herbs or
herbal formulae in depression. In the systematic reviews
described above, either only Chinese databases were searched
or the review only included trials of one speci�c formula. A
systematic review was conducted to address this gap (sup-
plementary systematic review) and the results are described
below.
4 Evidence-Based Complementary and Alternative Medicine
4.2. Supplementary Systematic Review. A total of 1600 cita-
tions were retrieved (151 from the initial search; 1676 from
the comprehensive searches of which 1449 remained aer
removing duplicates). No unpublished trials were identi�ed
from the trials register. Forty-�ve potentially relevant cita-
tions were selected from these. Trials were identi�ed of Chi-
nese herbs in the treatment of depression, in perimenopausal
depression, poststroke depression and depression associated
with other medical and psychiatric conditions, and in the
prevention of postnatal depression. For depression as the
primary diagnosis, no nonrandomised controlled trials were
located but two uncontrolled studies were located: one in
which 40 cases of “melancholia” were treated with a formula
called modi�ed Wen Dan Tang [28] and the other in which
20 patients with prolonged partial remitted major depressive
disorder associated with fatigue or loss of energy were treated
with Japanese formulae comparable to the two Chinese
formulae: LiuWeiDiHuangWan and BaiWeiDiHuangWan
[29].eRCTs [30–38] are discussed in the following section,
and Figure 1 shows a summary of the selection process and
the excluded studies [28, 29, 39–72].
4.2.1. Summary of Trials Located. A total of nine reports
of controlled trials of Chinese herbs in depression were
identi�ed [30–38] (see Table 1 for a summary of the trials).
Two reports appeared to be of diﬀerent outcomes from
one trial [31, 32]. In all cases, the trials were described as
RCTs. Participants had been diagnosed with depression by
various means: using the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) criteria, the Chinese Clas-
si�cation of Mental Disorders (CCMD-3) criteria, CCMD-
3 plus the International Classi�cation of Diseases (ICD-10),
and Chinese medicine diagnostic methods. In 7 trials, the
inclusion criteria included a minimum score on the HAM-D
scale. e minimum scores required were generally between
17 and 20 re�ecting mild-to-moderate depression. However,
the mean scores were higher than this in some trials (and
over 30 in two trials), suggesting that more severe cases of
depressionwere included. Two trials were placebo-controlled
[34, 38] and one was a double-placebo-controlled trial [31,
32]. Two trials compared a Chinese herbal formula with
the antidepressants: �uoxetine and maprotiline, respectively
[30, 33]. In two trials, Chinese herbs combined with an
antidepressant were compared against antidepressant alone
[35, 36]. In both cases, the Chinese herbs were combined
with a tricyclic antidepressant but in Yang et al.’s study [35],
the comparison was against an SSRI. e �nal trial was a 3-
arm trial comparing two diﬀerent Chinese herbal formulae
combined with �uoxetine against �uoxetine alone [37].
4.2.2. Setting, Size, and Duration. All trials had been con-
ducted in China and patients appeared to have been recruited
from a variety of sources.e authors were based at hospitals
or medical colleges and one could assume that this is where
the trials were conducted but this was not explicitly stated in
all cases. e number of subjects recruited ranged from 60 to
164 (total 756) and the treatment duration ranged between
30 days and 12 weeks. None of the trials conducted a later
followup to ascertain whether changes were maintained or
whether remission was only temporary.
4.2.3. ChineseHerbs Investigated. All trials involved the use of
Chinese herbal formulae rather than a single herb. A variety
of diﬀerent Chinese herbal formulae were investigated. Of
the herbs included in the formulae, only one, Hypericum
(St John’s wort) has documented anti-depressive activity
[73]. is herb was included in the formula used in one
trial. According to the same reference source, four of the
herbs used have potential sedative or anxiolytic properties.
Preliminary evidence has also been reported in studies from
China on relevant eﬀects of several herbs included Xiao Yao
San [24].
4.2.4. Outcome Measures. e eﬀects of the herbal formulae
were assessed in 7 of the trials by comparing HAM-D
scores before and aer treatment. Rating scales used in
addition to HAM-D included the Self-Rating Anxiety Scale
(SAS), Self-Rating Depression Scale (SDS), Montgomery-
Asberg Depression Rating Scale (MADRS), Clinical Global
Impression (CGI), TCM syndrome and symptom diﬀerenti-
ation (TCM-SSD), and Treatment Emergent Symptom Scale
(TESS). In one trial, response was only measured by clinical
assessment of symptom improvement or resolution [30].
4.2.5. Reporting of Adverse Events. All but two trials reported
types of adverse events by intervention. Zhang et al. [38]
and Sun et al. [34] found there to be no statistical diﬀerence
between incidence of adverse events in the Chinese herb
group and the placebo group. A signi�cant diﬀerence was
reported between treatment with a Chinese herbal mixture
with or without an antidepressant compared with the antide-
pressant alone, with the herbal mixture apparently causing
reduced adverse event rates [31–33, 36, 37]. In the other
studies, a formal statistical comparison was not carried out
and adverse events simply reported by group.
4.2.6. Overall Quality of Methods and Reporting. All studies
were described as randomised but several did not describe
how randomisation had been carried out. e Jadad assess-
ment also revealed that an eﬀective process for blinding (or
masking) treatment was only described in three trials. From
the assessment based on the Downs and Black checklist,
the following items were found to be reported in few, if
any, studies: how recruitment to the study was carried out,
whether intervention and control groups were wellmatched
at baseline, which statistical tests were used, whether compli-
ance was reliable, and whether the study had suﬃcient power.
emean Jadad scorewas 2.4 (out of 5) and 3 trials scored
more than 3.emean adapted Downs and Black’s score was
17 (out of 28). Only two trials scored more than 20 (both of
which also scored 4 on the Jadad scale). e scores on each
of the aspects addressed by the Downs and Blacks checklist
varied from 5 to 11 (out of 11) for reporting, 0 to 1 (out of
3) for external validity, 1 to 6 (out of 7) for internal validity
(bias), and 3 to 6 (out of 6) for internal validity (confounding).
No trial discussed power or provided a rationale for the
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Records identiﬁed through from
initial database searches
Records identiﬁed through
comprehensive searches
Records screened Records excluded
Articles assessed for
eligibility
Studies included in
qualitative synthesis
9 reports
Based on title/abstract:
2 bipolar disorder [39, 40]
1 dysthymia [41]
6 menopausal depression [43–48]
1 postoperative depression [42]
8 poststroke depression [49–56]
2 premenstrual syndrome [57, 58]
1 prevention of  postnatal depression [59]
4 combination treatment [60–63]
1 effect of  educational intervention [64]
2 no control group [37, 38]
1 animal study [65]
Based on full text:
1 bipolar disorder [66]
2 combination treatment [67, 68]
4 not a clinical trial [69–72]
(𝑛 = 151)
(𝑛 = 1676)
(𝑛 = 1600)
(𝑛 = 1600) (𝑛 = 1555)
(𝑛 = 45)
(𝑛 = 8)
Records after duplicates removed
[28–36]
(𝑛 = 36)Articles excluded
F 1: Flowchart showing selection process.
number of participants recruited. Based on the risk of bias
assessment, trials were either at risk of bias or the overall risk
of bias was unclear.
4.2.7. Pooling of Results. e herbal formulae and control
treatments used, trial duration, and trial design all diﬀered to
such an extent that it was not possible to pool data to present
any meaningful statistics. Where changes in depression
scores were measured, clinically signi�cant reductions were
reported within groups with active treatment, either Chinese
herbs or antidepressants. However, between-group compar-
isons suggested that Chinese herbs were more eﬀective than
antidepressants [30], were comparable to antidepressants
[31–33], did not increase eﬀectiveness but reduced adverse
eﬀects or relapse rates when used as additive therapy with
antidepressants [35–37], or were more eﬀective than placebo
[34, 38].
4.3. Comparison with the Other Systematic Reviews. Only
three trials were located that hadnot been included in the pre-
vious reviews [30, 34, 36]. Two of these assessed the formula,
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Shugan Jieyu and the third, modi�ed Xiao Yao San. Two trials
were included in the previous review focusing on the Chinese
literature [33, 37], three were included in the systematic
review of Xiao Yao San formula [31, 32, 35, 37] and two were
in the Free and Easy Wanderer Plus review [31, 38]. None of
the trials were included in the reviews of Chaihu-Shugan-San
or Chinese herb/antidepressant combination treatment. A
comparison of the systematic reviews is presented in Table 2.
In terms of methodology and reporting, the current review
found similar issues to the previous systematic reviews.
ese included lack of reporting of whether groups were
matched on baseline characteristics, allocation concealment
or blinding of assessors. Little or no detail was provided
on dropout and intention-to-treat analysis. ese address
issues related to internal validity. As described above, the
current review also revealed issues aﬀecting external validity
in that the process of recruitment of participants and the
speci�c location of the trial were not reported in most
trials.
An evaluation of the results of the meta-analyses and
the strength and quality of the supporting evidence was
conducted. e results are presented in Table 3. is demon-
strates that the overall evidence was generally of low quality
and even moderate evidence was compromised by aspects
such as the heterogeneity of the interventions and diagnoses.
5. Discussion
is paper provides an overall picture of the current evi-
dence base for Chinese herbal medicine in the treatment of
depression. Five published systematic reviews were located.
A supplementary systematic review to address a gap in the
coverage located eight trials, of which three had not been
included in previous systematic reviews.
Positive results were reported almost universally. ese
included one ormore of the following: greater anti-depressive
eﬀects than placebo, equivalent eﬀects to antidepressants,
less problems with adverse eﬀects than antidepressants, or
reduction of the adverse eﬀects caused by antidepressants
whenused in combination. In trials comparingChinese herbs
against antidepressants, lack of power calculations means
that it is unclear whether a lack of diﬀerence between the
Chinese herbal formula and the antidepressant is due to a
true diﬀerence or simply a trial that was underpowered to
detect a diﬀerence. �f the �CTs found, �ve scored less than
3 on the Jadad scale which suggests bias may have been
introduced. In several cases, the low scorewas due to blinding
being impossible but lack of information on withdrawals and
dropouts was also a problem. is �nding correlates with
previous reviews, which also reported low scores on Jadad or
unclear or high risk of bias for many of the included trials. In
fact, based on risk of bias assessments, all trials were either at
risk of bias or the extent of possible bias was unclear.
All 8 trials were conducted in China and the methods
used in most of the trials were similar. Diagnosis was
using conventional diagnostic frameworks and the response
measured using the HAM-D instrument. Patients appear to
have been recruited via hospitals in most cases but the exact
process of recruiting patients was not reported in any trial.
us, it is diﬃcult to assess whether the patients selected
were representative of the population from which they were
selected. Similarly, trials were reported to be randomised
but it is diﬃcult to judge whether allocation was eﬀectively
concealed. In fact, the limited reporting precludes an accurate
assessment of themethods and, therefore, the reliability of the
results. Again, this is a similar �nding to those of the other
systematic reviews in this area.
Herbs were used in combination and at least 6 diﬀerent
herbs appear to have been included in many of the formulae.
Several of the herbs have sedative or anxiolytic potential
activity which may be bene�cial in depressed patients [39].
e remaining herbs have a range of uses and actions and
it becomes more apparent why a formula such as Xiao Yao
Sanwith or without modi�cations might be used widely for a
range of conditions. It is also possible that using these herbs in
combination may produce eﬀects that would not be achieved
with each herb alone.
Chinese herbal mixtures are supplied as the dried plant
parts, pills or capsules, or in powder form [27]. Diﬀerent parts
of the plant are used and preparation of the dose may entail
processes such as decoctionwhich involves boiling.e eﬀect
of these processes on the activities of the component herbs
is diﬃcult to predict. In terms of trial design, blinding or
masking of the patient is, in many cases, impossible. Even if
pills or capsules are prepared, unblinding may take place due
to the smell of the herbs. is obviously may introduce some
bias on the part of the patient which is particularly relevant
in depression where the main outcome measure is based on
self-report. Blinding of assessors may limit the extent of bias
somewhat but was not reported in the trials included in this
paper, nor have other reviewers found consistent reporting of
blinding.
Two systematic reviews have focused on the formula Xiao
Yao San or a modi�cation of this [23, 24]. In practice, this
formula forms the basis for an array of modi�ed formulae.
From the Chinese medicine perspective, these are all based
on the core formula, with additional herbs added to address
speci�c problems. ey are referred to as modi�ed Xiao
Yao San or Jia wei Xiao Yao San (san means powder while
wan means pill). us, two preparations may have a similar
name but contain diﬀerent herbs [27]. is causes potential
problems in interpreting the results of trials using these
formulae. It also causes problems in practice in the reporting
of adverse events and checking for interactions.e formulae
used are considered safe by TCM practitioners based upon
experiential evidence but there is obviously a potential for
interactions and adverse eﬀects. Some insight into the more
frequent adverse eﬀects is revealed by the results of these
trials but the small size of the trials means that less common
adverse eﬀects may not have been encountered.
e issue of diagnostic frameworks is also worth consid-
ering when assessing the relevance of these trials to practice.
Chinese medicine recognises patterns of signs and symptoms
and diagnoses that do not �t with aWestern framework [27].
People who might be diagnosed in Western medicine with
depression may receive diﬀerent Chinese medical diagnoses
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T 3: Summary of results and supporting evidence (based on meta-analyses).
Outcome Intervention Control Result (95% CI) Evidence (participants) Quality∗ (comments)
HAM-D
score Chinese herbs + ADs ADs alone WMD −2.39 [−2.96, −1.83] 7 RCTs (576)
Low (trials unclear/high risk of
bias, varied herbs)
WMD −3.56 [−5.09, −2.03] 6 RCTs (506) Low (trials low quality,heterogeneity)
WMD −0.51 [−0.71, −0.31] 14 RCTs (921) Low (trials unclear/high risk ofbias, heterogeneity)
OR∗∗ 1.75 [1.26, 2.44] 8 RCTs (648) Low/moderate (varieddiagnoses)
Chinese herbs ADs WMD −3.09 [−5.13, −1.06] 2 RCTs (164) Low (trials high risk of bias,heterogeneity)
WMD 0.43 [−2.14, 2.99] 3 RCTs (NR) Low (trials unclear/high risk ofbias, publication bias)
OR∗∗ 1.09 [0.60, 1.98] 4 RCTs (250) Low/moderate (varieddiagnoses)
TESS score
Chinese herbs Placebo OR∗∗ 9.40 [5.57, 15.89] 3 RCTs (321) Low (heterogeneity)
Chinese herbs/ADs ADs alone WMD −2.51 [−3.18, −1.84] 4 RCTs (263) Low (heterogeneity)
Chinese herbs ADs WMD −1.86 [−2.57, −1.15] 1 RCT (60) Very low (single trial, high risk ofbias)
TESS: Treatment emergent symptoms and side eﬀects; NR: not reported; ∗Overall quality of the evidence was assessed based on reported quality/potential bias
in RCTs, heterogeneity, publication bias, consistency of interventions and diagnoses. ∗∗Odds ratios were based on a decrease of at least 50% in HAM-D scores.
depending on the overall pattern. Virtually all the trials have
used standardised Western-based diagnostic frameworks.
e advantage is more ready interpretation in a Western
context but the primary problem is whether the trials re�ect
usual Chinese medicine practice. Related to this is the fact
that virtually all the research has to date been conducted in
China so it is diﬃcult to translate the results into a Western
healthcare context.
None of the trials reviewed here conducted a followup
at a later date to ascertain duration of antidepressant eﬀects
aer the herbal treatment.e longest durationwas 12weeks.
Without this information it is impossible to establish whether
the herbal medicine had a temporary eﬀect or whether its
eﬀects were long lasting or to be able to calculate relapse
rates. National guidelines on the management of depression
[74] state that drugs administered for depression should be
continued for 6 months aer the last episode to avoid relapse.
If the same is true of herbal formulas, then a long-term
trial would be necessary to test long-term bene�ts of herbal
medication.
Analysis of the overall strength and quality of the
evidence from the various systematic reviews revealed a
number of aspects which compromise �rm conclusions on
the eﬀectiveness of Chinese herbal formulae in the treatment
of depression.
5.1. Limitations of is Review. Only systematic reviews
indexed in Western databases were included. However, the
Chinese literature was addressed to some extent in that each
of these systematic reviews involved searches of Chinese
databases. In the supplementary review, all except one of
the trials included were originally published in Chinese.
erefore, the data presented and quality assessments were
based on translations rather than the original reports.
6. Conclusions
Overall, this paper has provided an insight into the research
that has been conducted on Chinese herbs in depression.
e intention of this paper was to assess the eﬀectiveness of
Chinese herbal medicine treatments for depression. Positive
results were reported in all the trials identi�ed and in all
but one of the systematic reviews. ese results included
no signi�cant diﬀerences when compared with medication,
greater eﬀect than medication or placebo, and reduction in
adverse event rates when used as additive therapy. However,
because of limitations in the strength and quality of the
evidence, it has not proved possible to either fully substantiate
or disprove claims of eﬀectiveness ofChinese herbalmedicine
in the management of depression. Limitations in reporting
and in methodology, diﬀerent control interventions, and use
of varied formulae precluded any reliable conclusions. In
addition, virtually all trials located were for 12 weeks or less
so that it is unclear whether reported eﬀects were sustained
in the longer term. Adverse eﬀects were reported but trials
were generally small and the preparations used varied so
that further evidence on safety would be required for �rm
conclusions.
It is clear that a large number of trials of Chinese herbs
in depression have been conducted. Based on the �ndings of
the supplementary review, only a small proportion of these
are currently listed in Western databases. Similarly, in the
case of the systematic reviews, it is also possible that further
systematic reviews are available in the Chinese literature.
However, research to change or support practice in Western
12 Evidence-Based Complementary and Alternative Medicine
contexts needs to be accessible, thus supporting the rationale
for focusing on evidence found in theWestern literaturewhile
drawing attention to the wider literature on this topic.
Conclusions of potentially bene�cial eﬀects, particularly
for the formula Xiao Yao San and modi�ed versions of this
formula, need to be interpreted in the light of limitations
related to reporting and methods but also because of the
variation in the combinations of herbs used.
Nevertheless, this overview of the evidence indicates that
well-designed trials in a Western context may be worth
pursuing. ese will require decisions such as which frame-
work is used to diagnose depression, whether any �exibility
is allowed in the prescribing of Chinese herbs and the
most appropriate comparison intervention. It is possible
that pragmatic trials comparing overall care via diﬀerent
systems will be most informative. Reporting does need to
be addressed because it aﬀects how an RCT is judged,
particularly when scoring systems such as Jadad are used to
assess quality. Assessment of preference and expectations will
also be important in interpreting the results where disguising
the treatment is not possible.
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